Latest Fibrinolysis Stories

MARBURG, Germany, Dec. 19, 2012 /PRNewswire/ -- Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery. The Phase II prospective study, performed by CSL Behring and collaborators at the Hannover Medical School, Germany, enrolled 61...

Swanson Health Products now offers Swanson Ultra Maximum Strength Nattokinase for cardiovascular wellness. This new formula features patented NSK-SD® Japanese Nattokinase for super potent circulatory support. Fargo, ND (PRWEB) April 13, 2012 Nattokinase is an enzyme extracted from natto, a traditional dish from Japan made of fermented soybeans. The enzyme harvested is “fibrinolytic” and is shown to promote healthy blood flow to support cardiovascular and circulatory health....

Everyone is familiar with the pain of skinned knees. However, the complex pathway of proteins that works behind the scenes after the bleeding has stopped is not as well known. Central to this process is the production of plasmin, a powerful blood enzyme that disposes of blot clots. Doctors also harness the "clot busting" abilities of plasmin to treat patients who suffer heart attack or stroke. Now, a study published by Cell Press on March 8th in the journal Cell Reports provides remarkable...

By discovering how a blood clot-busting enzyme is switched on, researchers have unlocked a century-old atomic riddle that could lead to new treatments for clotting and bleeding disorders, and some cancers. Monash University researchers, led by Professor James Whisstock and Associate Professor Paul Coughlin, together with colleagues at the Australian Synchrotron have shown how the protein plasminogen is converted into plasmin, an enzyme that removes disease-causing clots and clears up...

Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden have been using a substance found in cancer and epilepsy drugs to help stimulate the body’s natural defense mechanism against blood clots. The body contains a system that helps break down blood clots before they can damage the heart, called the fibrinolytic system. This system “sprays” an enzyme on the clot before it can stop blood flow to the heart, causing a heart attack. This system can be compromised...

SEATTLE, Feb. 10, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that research on the antifibrinolytic agents it is developing has been published in the February 11, 2011 issue of the Journal of Biological Chemistry and selected by the editors as one of the top one percent of papers reviewed by the Journal in terms of significance and overall importance. This work from the laboratory of S. Paul Bajaj, Ph.D., demonstrates that unique antifibrinolytic agents can be...

The findings suggest a possible novel target for the treatment of hemophilia AA scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.The findings, from a study by Scripps Research Assistant Professor Laurent O. Mosnier, were published in a recent edition of Journal...

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents. These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding. "This is a good opportunity for Omeros and represents a potential life-saving treatment for patients. With the withdrawal of Trasylol® from the market...

PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA(TM) (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB...

NORDISTEMI: first trial to study the effect of early PCI after fibrinolysis in rural areas with very long transfer delays.Results from the NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction (NORDISTEMI) show that patients presenting with acute ST-elevation myocardial infarction (STEMI) in rural areas have a better treatment outcome with thrombolysis followed by immediate transfer for angiography than with thrombolysis and conservative, community-hospital follow-up.The...